HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer

Yasuyuki Kawamoto, Satoshi Yuki, Hideyuki Hayashi, Shintaro Nakano, Kentaro Sawada, Tetsuhito Muranaka, Hiroshi Nakatsumi, Takuro Saiki, Atsushi Ishiguro, Kazuaki Harada, Yoshimitsu Kobayashi, Ichiro Iwanaga, Kazuteru Hatanaka, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)vii63
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - 2018 Oct 1

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Kawamoto, Y., Yuki, S., Hayashi, H., Nakano, S., Sawada, K., Muranaka, T., Nakatsumi, H., Saiki, T., Ishiguro, A., Harada, K., Kobayashi, Y., Iwanaga, I., Hatanaka, K., Sakata, Y., Sakamoto, N., & Komatsu, Y. (2018). HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 29, vii63. https://doi.org/10.1093/annonc/mdy374.051